

SPARC/Sec/SE/2022/019

June 01, 2022

National Stock Exchange of India Ltd., Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051. **BSE Limited,** Market Operations Dept. P. J. Towers, Dalal Street, Mumbai - 400 001.

Ref: Scrip Code: NSE: SPARC; BSE: 532872

Dear Sir/Madam,

Sub: Disclosure under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Pursuant to Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit disclosure of Related Party Transactions for the half year ended March 31, 2022

We request you to kindly take the same on record and disseminate.

Thanking you,

Yours faithfully,

For Sun Pharma Advanced Research Company Limited

Dinesh Lahoti Company Secretary and Compliance Officer ICSI Membership No. A22471

Encl: As above

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction	Details of the counterparty		Type of related party transaction	Value of the related party transaction as approved by the audit committee		n In case monies are due to either party g as a result of the transaction		In case any fina incurred to mak corporate depo investments	e or give loan	Amount in Rs. Lak Details of the loans, inter-corporate deposits, advances or investments					
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance (As at October 01, 2021)	Closing balance (As at March 31, 2022)	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter- corporate deposit/ investment	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end- usage)
1	Sun Pharma Advanced Research Company Limited	Dilip S. Shanghvi	Non Executive Chairman / Promoter	Sitting Fees	N.A.	1.50	-			-		-	-	-	-	
2	Sun Pharma Advanced Research Company Limited	Dilip S. Shanghvi	Non Executive Chairman / Promoter	Outstanding Payable	N.A.	N.A	1.50			-		-	-	-	-	
3	Sun Pharma Advanced Research Company Limited	Dilip S. Shanghvi	Non Executive Chairman / Promoter	Exercise Price towards conversion of warrants into equity shares	N.A.	11,250.00	-			-	-	-	-	-	-	
4	Sun Pharma Advanced Research Company Limited	Sudhir V. Valia	Non Executive Director	Sitting Fees	N.A.	3.00	-			-	-	-	-	-	-	
5	Sun Pharma Advanced Research Company Limited	Rajamannar Tennati	Non Executive Director	Sitting Fees	N.A.	1.50	-			-	-	-	-	-	-	
6	Sun Pharma Advanced Research Company Limited	Bhavna Doshi	Independent Director	Sitting Fees	N.A.	3.00	-			-	-	-	-	-	-	
7	Sun Pharma Advanced Research Company Limited	Ferzaan Engineer	Independent Director	Sitting Fees	N.A.	2.70	-			-	-	-	-	-	-	
8	Sun Pharma Advanced Research Company Limited	Robert Jay Spiegel	Independent Director	Sitting Fees	N.A.	2.70	-			-	-	-	-	-	-	
9	Sun Pharma Advanced Research Company Limited	Anilkumar Raghavan	Chief Executive Officer	Remuneration	N.A.	268.28	-			-	-	-	-	-	-	

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction	Details of the counterparty		Type of related party transaction	Value of the related party transaction as approved by the audit committee		In case monies are as a result of the tr		In case any fina incurred to mak corporate depos investments	e or give loan	Details of the loans, inter-corporate deposits, advances or investments					
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance (As at October 01, 2021)	Closing balance (As at March 31, 2022)	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter- corporate deposit/ investment	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end- usage)
10	Sun Pharma Advanced Research Company Limited	Shanghvi Finance Private Limited	Holding Company	Loan taken (Line of Credit)	25,000.00 #	1,000.00	-			-	-	-	-	-	-	
11	Sun Pharma Advanced Research Company Limited	Shanghvi Finance Private Limited	Holding Company	Loan Repaid	N.A.	1,000.00	-			-	-	-		-	-	
12	Sun Pharma Advanced Research Company Limited	Shanghvi Finance Private Limited	Holding Company	Interest paid on Loan taken	236.60	3.07	-			-		-	-	-	-	
13	Sun Pharma Advanced Research Company Limited	Alkaloida Chemical Company ZRT	Enterprises under significant influence/are controlled by Key Management Personnel	Purchase of Goods*	500.00	0.85	5 -			-	-	-	-	-	-	
14	Sun Pharma Advanced Research Company Limited	Antique Stock Broking Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Receiving of services	768.00	-				-	-	-	-	-	-	
15	Sun Pharma Advanced Research Company Limited	OHM Laboratories Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Balance Payable	N.A.	N.A.	. 12.01	. 12.27	-	-	-	-	-	-	-	
16	Sun Pharma Advanced Research Company Limited	Spiegel Consulting LLC.	Enterprises under significant influence/are controlled by Key Management Personnel	Professional Fees Paid	246.35 #@	75.78	3 -			-	-	-	-	-	-	
17	Sun Pharma Advanced Research Company Limited	Spiegel Consulting LLC.	Enterprises under significant influence/are controlled by Key Management Personnel	Balance Payable	N.A.	N.A.		18.95	5 -	-	-	-	-	-	-	
18	Sun Pharma Advanced Research Company Limited	Sun Pharma Laboratories Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Royalty Income	4,222.45	2,150.34	-			-	-	-	-	-	-	

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction	Details of the counterparty		Type of related party transaction	/ Value of the related party transaction as approved by the audit committee		g as a result of the transaction		In case any fina incurred to mak corporate depo- investments	e or give loan	Amount in Rs. Lakh Details of the loans, inter-corporate deposits, advances or investments					
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance (As at October 01, 2021)	Closing balance (As at March 31, 2022)	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter- corporate deposit/ investment	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end- usage)
19	Sun Pharma Advanced Research Company Limited	Sun Pharma Laboratories Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Sale of services - R&D services	195.62	97.16				-		-		-	-	
20	Sun Pharma Advanced Research Company Limited	Sun Pharma Laboratories Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Purchase of Goods*	500.00	2.19	-			-		-	-	-	-	
21	Sun Pharma Advanced Research Company Limited	Sun Pharma Laboratories Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Balance Receivable	N.A.	N.A	. 1,228.35	1,372.78	3 -	-	-	-	-	-	-	
22	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Europe BV	Enterprises under significant influence/are controlled by Key Management Personnel	Reimbursement of expenses paid*	500.00	2.67	-			-	-	-	-	-	-	
23	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Europe BV	Enterprises under significant influence/are controlled by Key Management Personnel	Balance payable	N.A.	N.A	. 14.54	16.97	7 -	-	-	-	-	-	-	
24	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Inc.	Enterprises under significant influence/are controlled by Key Management Personnel	Reimbursement of expenses paid*	500.00	57.71				-	-	-	-	-	-	
25	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Inc.	Enterprises under significant influence/are controlled by Key Management Personnel	Receiving of services - R&D Service	2,091.12	891.57	-			-		-	-	-	-	
26	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Inc.	Enterprises under significant influence/are controlled by Key Management Personnel	Purchase of Goods*	500.00	4.23				-	-	-	-	-	-	
27	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Inc.	Enterprises under significant influence/are controlled by Key Management Personnel	Balance payable	N.A.	N.A	. 2,083.62	1,681.54	-	-	-	-	-	-	-	

Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction	Details of the counterparty		Type of related party transaction	Value of the related party transaction as	Value of transaction during the reporting			In case any fina incurred to mak			Amount in Rs. Lakh Details of the loans, inter-corporate deposits, advances or investments						
NO.					party transaction as approved by the audit committee	period Oct - Mar 2022	as a result of the tr	ansaction	incurred to mak corporate depo investments									
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance (As at October 01, 2021)	Closing balance (As at March 31, 2022)	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter- corporate deposit/ investment	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end- usage)		
28	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Sale of services - License fees / Royalty Income	6,504.73	5,044.19	-	· · · · · · · · · · · · · · · · · · ·		-	-	-		-	-			
29	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Sale of services - R&D services	2,020.04	1,436.42	-			-	-	-	-	-	-			
30	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Purchase of goods*	2,500.00	248.62	-			-	-	-	-	-	-			
31	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Purchase of property, plant & equipment	20.50	12.20	-			-	-	-	-	-	-			
32	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Rent expense (pertains to payment of lease liability)	1,000.42 #	104.62	-			-	-	-	-	-	-			
33	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Receiving of services - R&D Service	682.42	427.97	-			-	-	-	-	-	-			
34	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Reimbursement of expenses paid*	500.00	107.75	-			-	-	-	-	-	-			
35	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Reimbursement of expenses received*	500.00	11.84	-			-	-	-	-	-	-			
36	Sun Pharma Advanced Research Company Limited	Sun Pharmaceutical Industries Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Balance Receivable	N.A.	N.A	. 642.66	1,535.71	-	-	-	-	-	-	-			

Disclosure on Related Party Transaction under Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the half year ended March 31, 2022

																Amount in Rs. Lakhs
Sr. No.	Details of the party (listed entity /subsidiary) entering into the transaction	Details of the counterparty		Type of related party transaction	ty Value of the related party transaction as approved by the audit committee		In case monies are due to either party g as a result of the transaction		 In case any financial indebtedness is incurred to make or give loans, inter- corporate deposits, advances or investments 			Details of the loans, inter-corporate deposits, advances or investments				
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance (As at October 01, 2021)	Closing balance (As at March 31, 2022)	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost	Tenure	Nature (loan/ advance/ inter- corporate deposit/ investment	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end- usage)
37	Sun Pharma Advanced Research Company Limited	Taro Pharmaceuticals Industries Limited		Sale of services - R&D services	14.42	12.31	-			-	-	-	-	-	-	-
38	Sun Pharma Advanced Research Company Limited	Taro Pharmaceuticals Industries Limited	Enterprises under significant influence/are controlled by Key Management Personnel	Balance Receivable	N.A.	N.A.	1.25	11.38	3 -	-	-	-	-	-	-	-

Note :

N.A. denotes Not Applicable Values mentioned under the column "Value of the related party transactions as approved by the Audit Committee" are for FY22 except for multi year related party transactions, which are tagged seperately

Represent aggregate value of multi year related party transaction

@ Approval granted by the audit committee in foreign currency are disclosed in INR, basis the closing exchange rate as on March 31, 2022

* These transactions are also within the limits of overall aggregate omnibus limit granted by the Audit Committee